Ethylphenidate

Ethylphenidate (EPH) is a central nervous system (CNS) stimulant and the ethyl analog of methylphenidate. Ethylphenidate acts as a norepinephrine–dopamine reuptake inhibitor, meaning it effectively boosts the levels of the norepinephrine and dopamine neurotransmitters in the brain, by binding to, and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. Ethylphenidate, being almost identical to methylphenidate in both structure and pharmacodynamics, likely also doesn't solely act as a "classical" reuptake inhibitor but primarily as an inverse agonist at the dopamine transporter (DAT), inducing dopamine transporter reversal and subsequent dopamine release from the axon terminal into the synaptic cleft in a manner similar to but distinct from amphetamines. Ethylphenidate has appeared as a novel psychoactive substance (NPS) and has been reported in some regions as a recreational stimulant. It has been marketed through unregulated channels, where purity, dosage, and composition may vary. Its abuse potential is related to dopaminergic activity, particularly DAT interactions. Rapid delivery routes that produce higher concentrations in the brain may increase reinforcing effects and the likelihood of compulsive use. Ethylphenidate has been reported to produce stimulant effects comparable to those of cocaine in some contexts due to its activity at dopamine transporters; however, direct comparisons of potency, subjective effects, and abuse liability between ethylphenidate and cocaine are limited.